An overview of the FIGARO-DKD trial, which evaluated cardiovascular and renal outcomes in patients with type 2 diabetes and CKD treated with finerenone. Rajiv Agarwal, MD, MS: The FIGARO-DKD trial is ...

Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. In ...

kidneyintelX.dkd outperformed the Kidney Failure Risk Equation (KFRE) in predicting kidney function decline or kidney failure in diabetic kidney disease, demonstrating superior discrimination and ...

BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership, has announced the launch of a 5-year project with the aim to improve prevention and management ...

Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...

—Youth-onset T2D carries a higher risk of diabetic kidney disease than both adult-onset T2D of similar duration and T1D. Is there a path to prevention and slowing progression? The leading cause of end ...

Please provide your email address to receive an email when new articles are posted on . Finerenone added to a SGLT2 inhibitor provided more CV and renal benefits than finerenone alone. Data were ...

Kidney or renal biopsy or puncture procedure concept photo. Getty Images New findings could help guide clinicians as to when to consider ordering kidney biopsies in patients with diabetes.

Among patients with diabetic kidney disease (DKD), those with anemia may especially reap cardiovascular benefits from finerenone treatment. Finerenone treatment reduces cardiovascular and kidney risks ...